Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-09-10
2002-11-12
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S323000, C530S330000
Reexamination Certificate
active
06479460
ABSTRACT:
BACKGROUND OF THE INVENTION
It has been established that regenerating bone marrow induces an osteogenic response in distant skeletal sites and that this activity is mediated by factors released into the circulation by the healing tissue [(Bab I., et al. (1985) Calcif. Tissue Int. 37:551; Foldes, J., et al. (1989) J. Bone Min. Res. 4:643; Einhorn, T. A., et al. (1990) J. Bone Joint Surg. Am. 72:1374; Gazit D., et al. (1990) Endocrinology 126:2607; Mueller, M., et al. (1991) J. Bone Min. Res. 6:401]. One of these factors, a 14-amino acid osteogenic growth polypeptide (OGP) (SEQ ID NO: 1), identical with the C-terminus of histone H4, has been recently identified in the regenerating bone marrow [Bab, I., et al. (1992) EMBO J. 11:1867; EP-A-0 384 731] and in human serum [Greenberg, Z et al (1995) J. Clin. Endocrinol. Metab 80:2330].
Synthetic osteogenic growth polypeptide, identical in structure with the native molecule, has been shown to be a potent stimulator of proliferation of osteoblastic and fibroblastic cells in vitro. This synthetic polypeptide also stimulates osteoblastic cell alkaline phosphatase activity. When injected in vivo to rats, at very small doses, the synthetic osteogenic growth polypeptide increases bone formation and trabecular bone mass [Bab, I., et al (1992) EMBO J. 11:1867].
Since the OGP molecule is too large for effective oral administration, it is of therapeutic importance to identify peptides, shorter than the full length OGP, that retain the OGP activity and can be modified into a stable preparation, suitable for the oral treatment of several pathological conditions, particularly conditions involving loss of bone tissue. Indeed, it was shown that the C-terminal penta-peptide of OGP, Try-Gly-Phe-Gly-Gly[OGP(10-14)] (SEQ ID NO: 61), retains the full OGP-like proliferative activity in vitro and osteogenic effect in vivo [WO94/20529 corresponding to Israel Patent Application No. 104954]. Due to its small size, this penta-peptide provides a useful basis for the design of further OGP analogs with improved activity, stability and bioavailability.
In search for yet improved osteogenically active substances, the inventors have now found novel, synthetic pseudopeptide derivatives of OGP (SEQ ID NO: 1) and OGP(10-14) (SEQ ID NO: 61), which are the subject of the present application.
BRIEF DESCRIPTION OF THE INVENTION
The present invention relates to pseudopeptidic osteogenic growth polypeptide (OGP) analogs having the general formula:
wherein the substituents are as hereafter defined.
The invention also relates to cyclic peptidic or pseudopeptidic OGP analogs having the general formula:
wherein the substituents are as hereafter defined.
The invention also relates to pharmaceutical compositions comprising as active ingredients the compounds of formulae (I) and/or (II).
REFERENCES:
patent: 5461034 (1995-10-01), Rodan et al.
patent: A-0 384 731 (1990-08-01), None
patent: 572 122 (1993-12-01), None
patent: WO94/20529 (1994-09-01), None
Hocart et al. Effect of CH2NH and CH2NAC Peptide Bond Isosteres on the Antagonistic and Histamine Releasing Activities of a Luteinizing Hormone Releasing Hormone Analogue Journal fo Medicinal Chemistry. vol. 31, pp. 1820-1824. (1988).*
Moroder, L. et al., Hoppe Seylers Z. Physiol. Chem. 357(11): 1651-3 (Nov. 1976).
Rickard, D. J. et al., Dev. Biol. 161(1):218-28 (Jan. 1994).
Bab I., et al. Removal of tibial marrow induces increased formation of bone and cartilage in rat mandubular condyle (1985) Calcif. Tissue Int. 37:551-555.
Foldes, J., et al. Osteogenic response to marrow aspiration: increased serum osteocalcin and alkaline phosphatase in human bone marrow donors (1989) J. Bone Min. Res. 4:643-647.
Einhorn, T.A., et al. The Osteogenic response to distant skeletal injury (1990) J. Bone Joint Surg. Am. 72:1374-1378.
Gazit D., et al. Regenerating marrow induces systemic increase in oseto- and chondrogenesis (1990) Endocrinology 126:2607-2613.
Mueller, M., et al. A systemic acceleratory phenomenon (SAP) accompanies the regional acceleratory phenomenon (rap) during healing of a bone defect in the rat (1991) J. Bone Min. Res. 6:401-410.
Bab, I., et al. Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity (1992) EMBO J. 11:1867-1873.
Greenberg, Z., et al. Structural and functional characterization of osteogenic Growth peptide from human serum: identity with rat and mouse homologs (1995) J. Clin. Endocrinol. Metab 80:2330-2335.
Morodor, L., et al (1976) Physiol. Chem. 357:1651.
Merrifield (1969) Adv. Enzymol. 32:221.
Stewart, J.M., Young, J.D., (1984) In: Solid Phase Peptide Synthesis. Pierce Chemical Co.: Rockford, IL, pp. 1-75.
Greenberg, Z., et al. Mitogenic action of osteogenic growth peptide (OGP): Role of amino and carboxy-terminal regions and charge (1993) Biochim Biophys Acta 1178:273-280.
Lender, A., et al Design and synthesis of sulfur-free cyclic hexapeptides which contain the rgd sequence and bind to the fibrinogen GP IIb/IIIa receptor (1993) Int. J. Peptide Protein Res., 42:509-517.
Nishino, N., et al Sequence dependence in solid-phase-synthesis cyclization cleavage for cyclo(-arginyl-glycyl-aspartyl-phenylglycyl-) (1992) Tetrahedron Letters, 33:1479-1482.
Cheung, S.T. and Benoiton, N.L., N-Methylamino acids in peptide synthesis V. The synthesis of N-tert-butyloxycarbonyl, N-methylamino acids by N-methylation (1997) Can. J. Chem., 55:906-.
Sasaki, Y. and Coy, D.H., Solid phase synthesis of peptides containing the CH2NH peptide bond isostere (1987) Peptides, 8:119-121.
Fehrentz, J.-A. and Castro B., An efficient synthesis of optically active &agr;-(t-Butoxycarbonylamino)-aldehydes from &agr;-amino acids (1983) Synthesis, pp. 676-678.
Hocart, S.J., et al Effect of the CH2NH and CH2NAc peptide bond isosteres on the antagonistic and histamine relating activities of a lutenizing hormone releasing hormone analogue (1988) J. Med. Chem. 31:1820-1824.
Wilchek, M. and Bayer, E.A., (1990) Methods Enzymol 184:5.
Rickard, D.J., et al (1994) Biology, 161:218.
Bab, I and Einhorn T.M. Polypeptide factors regulating osteogenesis and bone marrow repair (1994) J. Cellular Biochemistry 55:358-365.
Robinson I. et al. Osteogenic growth peptide regulates proliferation and osteogenic maturation of human and rabbit bone marrow stromal cells (1995) J. of Bone and Min. Res. 10(5):690-696.
Bab, I. et al. Regulatory role of osteogenic growth peptide in proliferation, osteogenesis and hemopoiesis (1995) Clinical Orthopaedics and Related Research 313:64-68.
Gurevitch O. et al. Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice (1996) Blood 88(12):4719-4724.
Bab I. Postablation bone marrow regeneration: an in vivo model to study differential regulation of bone formation and resorption (1995) Bone 17(4):437S-441S.
Bab I. Regulatory role of osteogenic growth polypeptide in bone formation and hemopoiesis (1993) Critical Reviews in Eukaryotic Gene Expression 3(1):31-46.
Bab Itai
Chorev Michael
Gazit Dan
Muhlrad Andras
Shteyer Arie
Gupta Anish
Haddaway Keith
Kinberg Robert
Low Christopher S. F.
Venable
LandOfFree
Synthetic peptides and pseudopeptides having osteogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic peptides and pseudopeptides having osteogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptides and pseudopeptides having osteogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2991624